Clinical trials are available for patients with an isocitrate dehydrogenase (IDH) mutation with hematologic malignancies and solid tumors

Committed to research

Inspired by patients and frustrated by the limitations of conventional approaches to cancer treatment, Agios is forging a new and different path to treating cancer by targeting cellular metabolism. Agios is committed to researching the role of IDH in cancer.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

For more information on these and other trials for patients with IDH mutations, visit clinicaltrials.gov.

Name

Description

  • AG120-C-001 (NCT02074839)
  • Investigational Agent: AG-120
  • Phase: I
  • Status: Ongoing study, but not recruiting participants

Dose-escalation and expansion study of orally administered AG-120 in patients with advanced hematologic malignancies with an IDH1 mutation

  • AG881-C-001 (NCT02492737)
  • Investigational Agent: AG-881
  • Phase: I
  • Status: Ongoing study, but not recruiting participants

Study of orally administered AG-881 in patients with advanced hematologic malignancies with an IDH1 and/or IDH2 mutation

Name

Description

  • AG120-C-002 (NCT02073994)
  • Investigational Agent: AG-120
  • Phase: I
  • Status: Ongoing study, but not recruiting participants

Study of orally administered AG-120 in patients with advanced solid tumors, including glioma, with an IDH1 mutation

  • AG881-C-002 (NCT02481154)
  • Investigational Agent: AG-881
  • Phase: I
  • Status: Recruiting

Study of orally administered AG-881 in patients with advanced solid tumors, including gliomas, with an IDH1 and/or IDH2 mutation

  • AG120-C-005 (NCT02989857)
  • Investigational Agent: AG-120
  • Phase: III
  • Status: Recruiting

Study of AG-120 in previously treated, advanced cholangiocarcinoma with IDH1 mutations (ClarIDHy)

These represent Agios-sponsored research for oncology therapeutic agents AG-120 and AG-881.

Learn about cancer clinical trials for patients with IDH mutations

Contact Agios Medical Affairs to learn more about the Agios-sponsored clinical trials shown here.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Phone: 1.833.228.8487

References
  1. Krell D, Mulholland P, Frampton AE, Krell J, Stebbing J, Bardella C. IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. Future Oncol. 2013;9(12):1923-1935.
  2. Yan H, Parsons W, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
  3. Kerr DA, Lopez HU, Deshpande V, et al. Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations. Am J Surg Pathol. 2013;37(6):787-795.
  4. Turkalp Z, Karamchandani J, Das S. IDH mutation in glioma: new insights and promises for the future. JAMA Neurol. 2014;71(10):1319-1325.
  5. Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17(1):72-79.
  6. Grassian AR, Pagliarini R, Chiang DY. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol. 2014;30(3):295-302.
  7. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499-2508.
  8. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27(25)4150-4154.
  9. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469-474.

Keep Me Informed

Receive the latest information about IDH mutations and their role in cancer from Agios.
This information is intended for healthcare professionals.



*Required fields

I would like to receive future communications about IDH mutations from Agios focused on (select one or more):